Renovaro Inc. (NASDAQ:RENB) Major Shareholder Anderson Wittekind William Sells 50,000 Shares

Renovaro Inc. (NASDAQ:RENBGet Free Report) major shareholder Anderson Wittekind William sold 50,000 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $1.51, for a total value of $75,500.00. Following the transaction, the insider now owns 1,034,275 shares of the company’s stock, valued at $1,561,755.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Anderson Wittekind William also recently made the following trade(s):

  • On Friday, July 5th, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The stock was sold at an average price of $1.55, for a total value of $93,000.00.
  • On Monday, July 1st, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The stock was sold at an average price of $1.56, for a total value of $93,600.00.
  • On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The shares were sold at an average price of $1.50, for a total value of $22,006.50.
  • On Tuesday, June 25th, Anderson Wittekind William sold 20,000 shares of Renovaro stock. The stock was sold at an average price of $1.58, for a total value of $31,600.00.
  • On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The stock was sold at an average price of $1.58, for a total value of $79,000.00.

Renovaro Stock Performance

NASDAQ RENB opened at $1.54 on Tuesday. The business has a 50 day simple moving average of $1.40 and a 200 day simple moving average of $2.52. Renovaro Inc. has a 52-week low of $0.46 and a 52-week high of $5.25. The stock has a market cap of $227.17 million, a price-to-earnings ratio of -1.97 and a beta of 0.60.

Renovaro (NASDAQ:RENBGet Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Renovaro

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in shares of Renovaro during the 1st quarter worth approximately $46,000. Tidal Investments LLC bought a new position in shares of Renovaro during the 1st quarter worth approximately $98,000. Finally, Vanguard Group Inc. grew its stake in shares of Renovaro by 904.0% during the 1st quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock worth $10,379,000 after acquiring an additional 3,526,565 shares in the last quarter. 71.41% of the stock is owned by institutional investors.

About Renovaro

(Get Free Report)

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.

Read More

Receive News & Ratings for Renovaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovaro and related companies with MarketBeat.com's FREE daily email newsletter.